Here we seek to assist the FDA in its evaluation of topical products by developing, evaluating and improving a framework of physiologically based absorption and pharmacokinetic models for dermal absorption in response to the FDA call: Physiologically Based Absorption and Pharmacokinetic Modeling and Simulation for Non-gastrointestinally Absorbed Drug Products in Humans (RFA-FD-14-012), focusing on dermal absorption. We describe a framework of three physiologically based pharmacokinetic models to assist in this evaluation: 1. An analytical solution based on a Laplace Transform solution 2. A compartmental approach 3. A 3D numerical analysis to precisely mimic the geometry of the stratum corneum and processes that occur when a product is applied to the skin eg evaporation of some excipients, penetration of active and some excipients into the skin and transfer to deeper tissue and the systemic circulation This work is then validated by parameter sensitivity analyses, a comparison with of predictions with actual data observations and some in house validation studies. The final stage is an evaluation of the models using data from 2 CROs and 2 studies FDA are presently supporting that involve in vitro membrane, in vitro skin penetration, in vitro stratum corneum assays, in vivo stratum corneum assays and dermal assays. A key outcome here, as well as an adequate description of the data, is a population description of intra and intersubject variability and likely covariances. Our key goal is to predict active concentrations at their sites of action and in the blood over time.
This project addresses a key issue of importance to the FDA, improving the evaluation of equivalence for complex drug products, such as locally acting topical drug products. The FDA needs to understand how relate critical quality of drug products to their in vitro performance and then to in vivo performance, including the effect site, the blood and their clinical performance. This project develops of a framework of physiologically based absorption and pharmacokinetic models that define the interactions between the product and the skin and seeks to predict the drug concentration at the site of action, and drug plasma/blood concentration. These models are then validated and evaluated.
|Roberts, M S; Mohammed, Y; Pastore, M N et al. (2017) Topical and cutaneous delivery using nanosystems. J Control Release 247:86-105|
|Nastiti, Christofori M R R; Ponto, Thellie; Abd, Eman et al. (2017) Topical Nano and Microemulsions for Skin Delivery. Pharmaceutics 9:|
|Yousef, Shereen; Mohammed, Yousuf; Namjoshi, Sarika et al. (2017) Mechanistic Evaluation of Hydration Effects on the Human Epidermal Permeation of Salicylate Esters. AAPS J 19:180-190|
|Yousef, Shereen; Liu, Xin; Mostafa, Ahmed et al. (2016) Estimating Maximal In Vitro Skin Permeation Flux from Studies Using Non-sink Receptor Phase Conditions. Pharm Res 33:2180-94|
|Bäsler, Katja; Bergmann, Sophia; Heisig, Michael et al. (2016) The role of tight junctions in skin barrier function and dermal absorption. J Control Release 242:105-118|